Quality of Life as a Major Determinant of Medical Decision-Making

  • Robert Zittoun

Abstract

In this paper, I shall mainly consider the second part of the question: Not so much who defines quality of life; we know that it has been or can be done by several categories: philosophers, social scientists, physicians, companies (especially pharmaceutical companies), health administration, government ... But rather who makes medical-decisions and how determination of quality of life and other determinants may contribute to a medical decision (1). Medical decisions are mainly made by physicians, but through quality of life or other determinants, the other categories contribute to this decision.

Keywords

Allogeneic Bone Marrow Transplantation Autologous Bone Marrow Transplantation Health Administration Genous Leukemia Patient Individual Preference 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Moinpour CM., Feigl P., Metch B., Hayden KA., Meyskens FL., Crowley J.: Quality of life end points in cancer clinical trials: review and recommendations. Journal of the National Cancer Institute. 1989, 81: 485–495.PubMedCrossRefGoogle Scholar
  2. 2.
    O’Connor AMC., Boyd NF., Warde P., Stolbach L., Till JE: Eliciting preferences for alternative drug therapies in oncology: influence of treatment outcome description, elicitation tehcnique and treatment experience on preferences. Journal of Chronic Diseases. 1985, 40: 811–815.CrossRefGoogle Scholar
  3. 3.
    Torrance GW., Feeny D.: Utilities and quality-adjusted life years. International Journal of Technology Assessment in Health Care. 1989, 5: 559–575.PubMedCrossRefGoogle Scholar
  4. 4.
    Zittoun R., Mandelli F., Willemze R et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. New England Journal of Medicine 1995, 332: 217–223.PubMedCrossRefGoogle Scholar
  5. 5.
    Zittoun R., Suciu S., Solbu G et al. Comparison of quality of life (QOL) of patients with acute myelogenous leukemias (AML) in long-term first complete remission (CR) after bone marrow transplantation (BMT) - allogeneic or autologous - or intensive chemotherapy consolidation (ICC): EORTC-GIMEMA AML 8 A study. Blood 1995, 86, supp’. I: 433a.Google Scholar

Copyright information

© Springer Science+Business Media New York 1997

Authors and Affiliations

  • Robert Zittoun
    • 1
  1. 1.Service d’HématologieHôtel-DieuParis Cedex 04France

Personalised recommendations